Standard one year Herceptin treatment provides long-term benefit to patients with high risk of recurrence About 70% of women with locally advanced HER2-positive breast cancer were free of their disease three years after initiation of therapy when treated with Herceptin plus chemotherapy before surgery, compared to only around 50% of patients receiving pre-operative chemotherapy alone.
More...